Dcgi Approves Zyduss Oxemia For Ckd Induced Anaemia
Oxemiatm Is A Hypoxia-Inducible Factor-Prolyl Hydroxylase (Hif-Ph) Inhibitor That Is Taken Orally. In The Dream-D And Dream-Nd Phase Iii Clinical Trials, Desidustat Met Its Primary Endpoints For Haemoglobin Improvement And Demonstrated A Good Safety Profile, As Well As Down Regulation Of Hepcidin, Improved Iron Mobilisation, And Ldl-C Reduction In Ckd Patients Zydus Lifesciences Announced That The Drug Controller General Of India (Dcgi) Has Accepted Its New Drug Application (Nda) For Oxemia (Desidustat), A First-Ofits-Kind Oral Medication For Anaemia Caused By Chronic Kidney Disease.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
